Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study  by Sakurai, Hiroyuki et al.
ORIGINAL ARTICLE
Survival Differences by Gender for Resected Non-small Cell
Lung Cancer
A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer
Registry Study
Hiroyuki Sakurai, MD,* Hisao Asamura, MD,* Tomoyuki Goya, MD,† Kenji Eguchi, MD,‡
Yoichi Nakanishi, MD,§ Noriyoshi Sawabata, MD, Meinoshin Okumura, MD, Etsuo Miyaoka, PhD,¶
and Yoshitaka Fujii, MD#; for the Japanese Joint Committee for Lung Cancer Registration
Introduction: Women with non-small cell lung cancer (NSCLC)
are more likely to have better survival than men. This study intended
to assess gender differences in the survival of these patients in a
large registry population.
Methods: In 2005, the Japanese Joint Committee for Lung Cancer
Registration performed a nationwide retrospective registry study
regarding the prognosis and clinicopathologic profiles of patients
who underwent resection for primary lung neoplasms in 1999. The
registry data of 12,509 patients with NSCLC were analyzed in terms
of gender differences in prognosis and clinicopathologic features.
Results: There were 8353 (66.8%) men and 4156 (33.2%) women
with a mean age at operation of 66.4 and 65.0 years, respectively
(p  0.001). Women had a higher incidence of adenocarcinoma
(p  0.001) and stage IA disease (p  0.001) than men. The overall
survival was significantly better in women than men. The 5-year
survival rates (5-YSRs) for women and men were 75.6 and 57.9%,
respectively (p  0.0000). According to histology, the overall
survival of women was significantly better than that of men for both
adenocarcinoma (5-YSR, 77.7 versus 61.9%, p  0.0000) and
nonadenocarcinoma (5-YSR, 59.3 versus 53.1%, p  0.035). In
adenocarcinoma, women had a significantly better prognosis than
men for pathologic stage I/II disease. However, in nonadenocarci-
noma, there was no significant prognostic difference between the
two genders in pathologic stage I/II disease.
Conclusions: Women with NSCLC, especially with an adenocarci-
noma histology, had better survival than men. Women were more
likely to have adenocarcinoma and stage IA disease, which might
account for the better prognosis in women.
Key Words: Gender, Non-small cell lung cancer, Prognosis, Cancer
registry.
(J Thorac Oncol. 2010;5: 1594–1601)
Previous studies have reported that lung cancer may rep-resent a somewhat different disease in men and women,
and some gender-specific differences have been suggested.1–6
Gender differences in the distribution of histologic types,
stage at presentation, and survival rates have been discussed.
Women with lung cancer are more likely to have adenocar-
cinoma histologically and a better prognosis than men.2–4,7–13
Several important prognostic factors have been identi-
fied, such as tumor, node, metastasis stage; performance
status; gender; age; and histology.14–16 Among these, the
female gender has been repeatedly mentioned as one of the
most important factors in both early and advanced lung
cancers. Although it has been speculated that women show
better survival, the relationship between gender and progno-
sis has not been clearly demonstrated in a large cohort.
In Japan, the task force committee of the Japanese Joint
Committee for Lung Cancer Registration has periodically
performed nationwide registry studies on the prognosis and
clinicopathologic profiles of lung neoplasms.14,17 The studies
are planned at 5-year intervals to observe changes and trends
in clinicopathologic features, such as the prognosis, staging,
and histologic distribution, of resected lung cancer patients in
Japan. Recently, the committee reported a retrospective reg-
istry study that focused on 13,010 cases of lung cancer
resected in 1999 after a 5-year follow-up period.14 This study
deals with the retrospective registry for patients with lung
cancer resected in 1999.
The aim of this study was to evaluate the characteristics
of non-small cell lung cancer (NSCLC) by gender with regard
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to clinicopathologic features and the relationship between
gender and prognosis.
PATIENTS AND METHODS
Registry
In 2005, the Japanese Joint Committee for Lung Cancer
Registration performed a nationwide retrospective registry
study on the prognosis and clinicopathologic profiles of
resected lung neoplasms in Japan. Only primary lung neo-
plasms that had been resected in 1999 at certified teaching
hospitals in Japan were considered for the registry, which
gave a follow-up period of at least 5 years. The committee
received the registries of 13,344 patients from 387 teaching
hospitals. The following 32 items were included in the ques-
tionnaire: gender, age, smoking status, clinical (c-) T, c-N,
c-M, c-stage, preoperative treatment, surgical procedure, ex-
tent of lymph node dissection, curability, residual tumor,
primary site by lobe, tumor diameter, histology, organ inva-
sion, pathologic (p-) T, p-N, p-M, p-stage, pleural dissemi-
nation, intrapulmonary metastasis, pleural cytology, location
of nodal metastasis, survival time, recurrence, and cause of
death. Recurrent or multiple lung cancers were not included
in this registry. Smoking status was recorded as to whether a
patient was a smoker within 1 month before the operation.
Operative mortality was defined as fatality from any cause
within 30 days of the operation or during the same hospital-
ization. All patients were staged on the basis of the sixth
edition of the International Union Against Cancer tumor,
node, metastasis classification of the malignant tumor staging
system published in 2002,18 and tumor histology was de-
scribed according to the World Health Organization classifi-
cation.19
Patients
Sixty-nine patients (0.5%) with incomplete descriptions
of their tumor histology and 655 patients (5.0%) with low-
grade malignant tumor, nonepithelial tumor histology, or
histology of small cell carcinoma were excluded from the
study. In addition, 111 patients (0.8%) for whom gender was
not given were also excluded from this study. Therefore, this
study focused on the remaining 12,509 patients with non-
small cell histology (adenocarcinoma, squamous cell carci-
noma, large cell carcinoma, and adenosquamous carcinoma).
Statistical Analysis
The 2 and Student’s t tests were used to evaluate the
differences in categorical variables and continuous variables,
respectively. The survival time was defined as the time
between the date of surgery and the last follow-up date. The
survival curves were estimated by the Kaplan-Meier method,
and differences in survival were assessed by the log-rank test.
Overall survival (OS) was defined as the time between
operation and death from any cause, except for cases of a
death within 30 days of the operation and during the same
hospitalization. Disease-specific survival (DSS) was defined
as the time between operation and cancer-related death,
where deaths from causes other than lung cancer were con-
sidered censored. Multivariate analysis by Cox’s proportional
hazards ratio model was used to test the significance of
prognostic factors including gender, age, smoking status
(current smoker versus non-/ex-smoker), surgical procedure,
histology, curability, tumor size, p-T status, and p-N status.
Significance was defined as a p value less than 0.05.
RESULTS
Clinicopathologic Features
There were 8353 (66.8%) men and 4156 (33.2%)
women. The clinicopathologic characteristics of the genders
are summarized in Table 1. There were 107 (0.9%), 29
(0.2%), 134 (1.1%), and 181 (1.4%) patients who were
missing data regarding operative mode, lymph node dissec-
tion, surgical curability, and pathologic stage, respectively.
These percentages were within an acceptable range as a
registry database.
The mean age at surgical resection for women (65.0
years) was significantly younger than that for men (66.4
years). With regard to smoking status according to histology,
the proportion of current smoker was 17.3% for men and
2.4% for women in adenocarcinoma histology (p 0.001). In
TABLE 1. Characteristics of Patients with Resected
Non-small Cell Lung Cancer
Characteristics
Men
(n  8353)
Women
(n  4156) p
Age (yr)
Mean 66.4  9.4 65.0  10.1 0.001
Smoking status
Current smoker 1598 (19.2%) 145 (3.5%) 0.001
Nonsmoker/ex-smoker 6746 (80.8%) 3985 (96.5%)
Operative mode
Pneumonectomy 560 (6.7%) 98 (2.4%) 0.001
Lobectomy 6750 (81.5%) 3500 (84.6%) 0.226
Segmentectomy/wedge 975 (11.8%) 537 (13.0%) 0.097
Lymph node dissection
Mediastinohilar 6375 (76.5%) 3101 (74.7%) 0.410
Hilar only/none 1907 (22.9%) 1023 (24.7%) 0.086
Unknown 48 (0.6) 26 (0.6) 0.732
Surgical curability
Complete 7423 (89.9%) 3734 (90.7%) 0.736
Incomplete 735 (8.9%) 320 (7.8%) 0.052
Unknown 101 (1.2%) 62 (1.5%) 0.199
Operative mortality 222 (2.7%) 31 (0.7%) 0.001
Histology
Adenocarcinoma 4498 (53.9%) 3670 (88.3%) 0.001
Squamous cell carcinoma 3305 (39.6%) 359 (8.6%) 0.001
Large cell carcinoma 403 (4.8%) 69 (1.7%) 0.001
Adenosquamous cell carcinoma 145 (1.7%) 58 (1.4%) 0.162
Pathologic stage
IA 2627 (31.9%) 2105 (51.4%) 0.001
IB 1912 (23.2%) 694 (16.9%) 0.001
IIA 255 (3.1%) 105 (2.6%) 0.106
IIB 1074 (13.1%) 242 (5.9%) 0.001
IIIA 1349 (16.4%) 498 (12.1%) 0.001
IIIB/IV 1014 (12.3%) 453 (11.1%) 0.070
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nonadenocarcinoma histology, the proportion of current
smoker was 21.3% for men and 12.1% for women (p 
0.001). In addition, the proportion of current smoker in
women also showed significant difference between histologic
types (adenocarcinoma versus nonadenocarcinoma) (p 
0.001), and the difference between histologic types was also
significant in men (p  0.001). Deaths within 30 days of the
operation, which were included in operative mortality, were
97 patients (1.2%) for men and 22 (0.5%) for women (P 
0.001). Although adenocarcinoma was the most common
histologic type in both genders, the distribution of histologic
types was significantly different between the genders. The
distribution according to histologic type in men and women is
shown in Figure 1. Women had significantly more adenocar-
cinoma (p  0.001) and less squamous cell carcinoma (p 
0.001) than men. As for the pathologic stage, women had a
significantly higher incidence of stage IA disease than men
(p  0.001).
Survival by Gender
The overall 5-year survival rates (5-YSRs) for men and
women were 57.9 and 75.6%, respectively. The survival
curves are shown in Figure 2. Women had significantly better
survival than men (p  0.0000). According to the histologic
type, women had significantly better overall survival (OS)
than men with adenocarcinoma (5-YSR, 77.7 versus 61.9%,
p  0.0000). In nonadenocarcinoma, women again had sig-
nificantly better OS than men (5-YSR, 59.3 versus 53.1%,
p  0.035) (Figure 3). The prognosis between women and
men was further studied with regard to histologic type and
pathologic stage. In patients with adenocarcinoma histology
and pathologic stage I/II disease, women had significantly
better OS than men (Figures 4A and 5A). In contrast, there
was no significant OS difference between the genders among
FIGURE 1. Distribution of histologic types between men
and women. AD, adenocarcinoma; SQ, squamous cell carci-
noma; LG, large cell carcinoma; AS, adenosquamous cell car-
cinoma.
FIGURE 2. Overall survival curves based on gender. The
5-year survival rates of female (n  4091) and male (n 
8008) patients are 75.6 and 57.9%, respectively. The differ-
ence in survival between the genders is significant (p 
0.0000).
FIGURE 3. Overall survival curves according to gender in
adenocarcinoma (A) and nonadenocarcinoma (B). The 5-year
survival rate for adenocarcinoma is 61.9% for male patients
and 77.7% for female patients. The difference in survival is
significant (p  0.0000). The 5-year survival rate for nonade-
nocarcinoma is 53.1% for male patients and 59.3% for fe-
male patients. The difference in survival is significant (p 
0.035).
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patients with nonadenocarcinoma histology and pathologic
stage I/II disease (Figures 4B and 5B).
Disease-specific 5-YSRs for men and women were 64.9
and 79.2%, respectively (Figure 6). Women had significantly
better DSS than men (p  0.0000). According to histologic
type, women had significantly better 5-year DSS than men
with adenocarcinoma (Figure 7A). However, in nonadenocar-
cinoma, there was no statistical difference in DSS between
genders (Figure 7B). Regarding histologic type and patho-
logic type, the difference between genders in DSS was
significant only in patients with adenocarcinoma histology
and pathologic stage I disease (Figures 8 and 9).
In a Cox proportional hazards model to predict OS, the
following factors persisted as important prognostic factors:
gender, age, surgical procedure, histology, curability, tumor
size, p-T status, and p-N status (Table 2). Gender had impact
on survival with relative risk for women of 0.63 (p  0.000;
95% confidence interval 0.58–0.68). Smoking status was not
statistically significant or important determinant of survival,
with relative risk for current smoker of 1.00 (p  0.94; 95%
confidence interval 0.93–1.09).
DISCUSSION
In this Japanese Lung Cancer Registry Study of 12,509
patients with resected NSCLC, women showed significantly
better survival than men after resection. Female gender was
one of the statistically positive independent predictors of
survival in this registry. This better survival for women was
observed regardless of the histologic type (adenocarcinoma
or nonadenocarcinoma). Many other studies that have eval-
uated the effect of gender on the lung cancer prognosis have
also suggested that women have a survival advantage, but the
reasons for this survival advantage have remained un-
known.3,4,8,11,20 Genetic, metabolic, and hormonal factors
have been proposed as potential explanations for the survival
benefit experienced by women.21–23
The histology of NSCLCs among women was dis-
tinctly different from that among men, although adenocarci-
noma was the most common histologic type in both genders
in this study. Women had so much higher incidence of
adenocarcinoma than men. Adenocarcinoma accounted for
approximately 90% of resected NSCLC in women, in con-
trast to only 54% in men. In addition, a large proportion of
FIGURE 4. Overall survival curves according to gender of
pathologic stage I in adenocarcinoma (A) and nonadenocar-
cinoma (B). The 5-year survival rate for pathologic stage I in
adenocarcinoma is 78.6% for male patients and 90.0% for
female patients (p  0.0000). The 5-year survival rate for
pathologic stage I in nonadenocarcinoma is 65.4% for male
patients and 72.8% for female patients (p  0.058).
FIGURE 5. Overall survival curves according to gender of
pathologic stage II in adenocarcinoma (A) and nonadenocar-
cinoma (B). The 5-year survival rate for pathologic stage II in
adenocarcinoma is 47.5% for male patients and 57.5% for
female patients (p  0.018). The 5-year survival rate for
pathologic stage II in nonadenocarcinoma is 53.5% for male
patients and 61.9% for female patients (p  0.28).
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resected NSCLC in females was stage IA disease. In Japan,
there have been opportunities of resecting small-sized lung
cancers since a computed tomography (CT) screening for
lung cancer was introduced in early 1990s. Most of the lung
cancers detected by CT screening were likely to be small-
sized and slow-growing adenocarcinomas.24,25 In addition,
people with lung cancer detected by CT screening accounted
for a large proportion of women.26 This would be one of the
reasons for the increased incidence of early-stage lung can-
cers among women. In fact, it has been reported that early-
stage lung cancers such as bronchioloalveolar carcinoma or
adenocarcinoma mixed bronchioloalveolar subtype tend to
occur frequently in nonsmoking women.27,28 These data in-
dicated that the difference in the pathobiologic characteristics
of adenocarcinoma between genders should be addressed.
The increased incidence of adenocarcinoma among
women may be attributed to several causes, including genetic,
biologic, and environmental factors. Genetic polymorphisms
and the mutation of specific genes have been examined as
possible causes of the predominance of the adenocarcinoma
histology in women.29–31 Epidermal growth factor receptor
and K-ras gene mutations have been detected more com-
monly in women than men and have been found mainly in
adenocarcinomas of the lung.29–32 Several reports33,34 have
investigated the relationship between the hormonal effects of
estrogen and the development of lung cancer, especially
adenocarcinoma, because the obvious biologic differences
between men and women are hormonal. These findings in this
study and the literature also suggest that the pathway of
carcinogenesis might be different between women and men.
On the other hand, we observed that women with
adenocarcinoma had a significantly better prognosis in both
stage I disease and stage II disease, whereas there was no
significant gender difference in nonadenocarcinoma patients
with either stage I or stage II. Based on the fact that adeno-
carcinoma was more common in women and they have better
prognosis, adenocarcinoma in women may be supposed to
have different pathobiologic behaviors than that in men. The
differences in lung cancer and its occurrence between women
and men have been found or hypothesized to be related to
several factors, such as differences in smoking habits and
genetic, biologic, hormonal, and other differences between
the genders.22,33,35,36 Adenocarcinoma has always represented
the majority of lung cancer cases among nonsmoking pa-
tients.7,22,23 The association between smoking and lung can-
cer is much stronger for small cell carcinoma, squamous cell
carcinoma, and large cell carcinoma than for adenocarcin-
oma.10,37 The proportion of smokers among men is known to
be significantly higher than that among women according
to several previous reports,1,38 although we were not able to
directly evaluate the effect of potential gender differences in
smoking habits because detailed data on tobacco exposure
were not recorded in this registry. According to a report by
the Health and Welfare Statistics Association in Japan, the
proportion of Japanese smokers was 70 to 60% for men,
FIGURE 6. Disease-specific survival curves based on gen-
der. The 5-year survival rates of female (n  3890) and male
(n  7131) patients are 79.2 and 64.9%, respectively. The
difference in survival between the genders is significant (p 
0.0000).
FIGURE 7. Disease-specific survival curves according to
gender in adenocarcinoma (A) and nonadenocarcinoma (B).
The 5-year survival rate for adenocarcinoma is 67.5% for
male patients and 80.8% for female patients. The difference
in survival is significant (p  0.0000). The 5-year survival
rate for nonadenocarcinoma is 61.6% for male patients and
66.3% for female patients. The difference in survival is not
significant (p  0.17).
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invariable 14% for women, from 1980s to 1990s.38 The
proportion of smokers for men is still higher than that for
women, although it has been reducing little by little.38 Smok-
ing is also closely related to cardiovascular and pulmonary
diseases, e.g., ischemic heart disease, cerebrovascular disor-
der, and pulmonary emphysema.39 These diseases might lead
to noncancerous death before cancer-specific death. Thus, the
better prognosis in women among patients with adenocarci-
noma might be partially attributed to the differences in the
incidence of noncancerous death between genders because
women would include fewer smokers than men. In fact,
Chang et al.8 reported that the female-gender advantage in
survival for resected NSCLC changed to no survival advan-
tage for females after propensity score matching (variables:
age, smoking status, histologic types, and pathologic stages)
between males and females. Hanagiri et al.40 showed that
there was no gender difference in cancer-related survival
regardless of a significant female-gender advantage in OS for
patients with resected lung adenocarcinoma.
In this registry study, according to relationship between
prognosis and the combination of histologic type and patho-
logic stage, women had significantly better DSS than men
only in patients with adenocarcinoma histology and patho-
logic stage I disease. Therefore, at the least, deaths of causes
other than lung cancer are likely to affect survival difference
between genders except for patients with stage I adenocarci-
noma. A significant female-gender advantage in stage I ade-
nocarcinoma persisted in DSS and OS. Stage I adenocarci-
noma in women would presumably include many
bronchioloalveolar carcinomas, which tend to occur often in
nonsmoking women, although histologic subtypes in adeno-
carcinoma was recorded in this registry.
Although the identification of factors that predispose to
operative mortality is beyond the scope of this study, an older
age at surgical resection and a higher number of pneumonec-
tomies for men could be related to the higher 30-day mortal-
ity among men in this series. The higher operative mortality
rate in male patients with lung cancer has been previously
reported.41,42
FIGURE 8. Disease-specific survival curves according to
gender for pathologic stage I in adenocarcinoma (A) and
nonadenocarcinoma (B). The 5-year survival rate for patho-
logic stage I in adenocarcinoma is 85.3% for male patients
and 93.5% for female patients (p  0.0000). The 5-year sur-
vival rate for pathologic stage I in nonadenocarcinoma is
77.1% for male patients and 81.9% for female patients (p 
0.14).
FIGURE 9. Disease-specific survival curves according to
gender for pathologic stage II in adenocarcinoma (A) and
nonadenocarcinoma (B). The 5-year survival rate for patho-
logic stage II in adenocarcinoma is 53.4% for male patients
and 60.0% for female patients (p  0.087). The 5-year sur-
vival rate for pathologic stage II in nonadenocarcinoma is
61.1% for male patients and 69.3% for female patients (p 
0.42).
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In conclusion, we found that women showed signifi-
cantly better 5-year survival than men after surgical resection
of NSCLC. Especially in adenocarcinoma, the survival ad-
vantage for women was significant in pathologic stages I and
II, whereas in nonadenocarcinoma, this gender difference was
not significant in pathologic stage I or II. Although adeno-
carcinoma is the most common histologic type in both gen-
ders, the proportion of adenocarcinoma and stage IA disease
in women was much greater than that in men. The incidence
of early-stage adenocarcinoma might reasonably account for
a better prognosis in women as a whole. Further studies
should focus on the identification of differences in the patho-
biological nature of early lung adenocarcinoma between
women and men.
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